

Anti-PD-1 (Nivolumab) Biotinylated Antibody

rev 06/20

CATALOG NO.: A2117-50 (50 µg)

BACKGROUND DESCRIPTION: Nivolumab, trade name Opdivo, is a medication used to treat cancer. It is used as a first line treatment for inoperable or metastatic melanoma in combination with Ipilimumab if the cancer does not have a mutation in BRAF, as a second-line treatment following treatment with Ipilimumab and if the cancer has a mutation in BRAF, with a BRAF inhibitor, as a second-line treatment for squamous non-small cell lung cancer, and as a second-line treatment for renal cell carcinoma.

ANTIBODY TYPE: Monoclonal

HOST/ISOTYPE: Human / IgG4

SOURCE: CHO cells

IMMUNOGEN: Human programmed cell death 1 receptor (PD1)

PURIFICATION: Affinity purified

FORM: Liquid


FORMULATION: In PBS, pH 7.2, 30% glycerol, 0.5% BSA, 0.5 mM EDTA and 0.03% proclin

SPECIES REACTIVITY: Human

STORAGE CONDITIONS: Store at -20°C; Store at -20°C. Avoid freeze / thaw cycles

APPLICATIONS AND USAGE: ELISA (1 µg)

This information is only intended as a guide. The optimal dilutions must be determined by the user



Direct ELISA shows that Anti-PD-1 (Nivolumab) Biotinylated antibody can bind to immobilized recombinant human PD-1 with a linear range of 0-5 ng/ml.

RELATED PRODUCTS:

Anti-PD-1 Antibody (A1384)
 Anti-PD-1 (Nivolumab), Humanized Antibody (A1307)
 Anti-PD-1 (Pembrolizumab), Humanized Antibody (A1306)
 Anti-PD-1 (Pembrolizumab) Biotinylated Antibody (A2073)

FOR RESEARCH USE ONLY! Not to be used on humans.